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A B S T R A C T
Pregnancy induced hypertension (PIH) is major contributor to maternal death in developing countries. Endothelin-1
(ET-1) is the most potent vasoconstriction agent known and its serum levels are increased in PIH. Therefore it is impor-
tant to elucidate maternal and neonatal factors which influence endothelin-1 serum levels. 100 pathological pregnancies
and 88 controls were analyzed for blood endothelin-1 and their anthropometric and clinical data were collected. In ma-
ternal blood ET-1 levels were strongly predicted by diagnosis, therapy and BMI, while umbilical cord ET-1 levels were
strongly predicted by gestational age, therapy and delivery termination. Positive correlation between BMI and ET-1 lev-
els suggest that obese pregnant women have increased risk for cardiovascular diseases. Inverse relationship between
Apgar and umbilical ET-1 indicates that ET-1 could be considered as a prognostic marker in cases of neonatal asphyxia.
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Introduction
Hypertensive disorders are major contributors to ma-
ternal deaths in developing countries. These data should
inform evidence-based reproductive health-care policies
and programs at regional and national levels1.
Pregnancy induced hypertension (PIH) affect up to
8–16% of pregnancies and has a significant portion of the
enhancement of perinatal and neonatal mortality and
morbidity. Some of those pregnancies often end in fetal
loss, neonatal asphyxia, intrauterine growth retardation
or premature birth, which carries a risk of serious neona-
tal complications2–4. PIH represents a spectrum of dis-
ease, whereby pregnant women suffer from newly onset
of hypertension, usually after the 20 weeks of gestation.
It could be manifested in several clinical entities, among
which the most significant are preeclampsia (PE) and
eclampsia, gestational hypertension, superimposed hy-
pertension and according to some authors HELLP syn-
drome (hemolysis, elevated liver enzymes, low plate-
lets)2. Last two decade recent literature has given the
most acceptable pathophysiological model of PE.
By definition, PE represent systemic syndrome of
pregnancy characterized by hypertension and proteinu-
ria5. Mostly, PE could be associated with some degree of
intrauterine growth restriction (IUGR). IUGR is a com-
mon diagnosis in obstetrics and represents second lead-
ing cause of perinatal mortality and morbidity, followed
only by prematurity6,7. Most acceptable definition of IUGR
is failure of the fetus to reach its own growth potential.
In the cases of PE growing potential of fetus could be in-
terrupted by shallow nutritional support from mother
mediated by placenta. Pregnancies with PE may appear
in two forms: most of them with restricted fetal growth
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and normal fetal growth. PE with restricted fetal growth
is followed by »ischemic pathophysiology model«.
Current evidence suggests that pregnancy disorders
such as PIH and IUGR seems to follow the same events
in placental milieu and fetal/maternal circulation8. How-
ever, it is important to stress that the exact pathological
sequence of these is mainly hypothetical. Although nu-
merous factors including genetic, immunologic, behav-
ioral and environmental influences have been implicated
in the pathogenesis of PIH, mainly PE, the focus of re-
cent studies is on link of endothelial dysfunction and hy-
pertension. Advanced in understanding about the patho-
physiology of these disorders put the new highlight on
molecular basis of these.
Fetal growth and development during pregnancy and
neonatal outcome depends primarily on protective, meta-
bolic and endocrine function of the placenta. Fetal-ma-
ternal relations in the placenta are clearly determined by
a range of vasoactive factors on the uteroplacental blood
flow. Research over the past decade indicate that vascu-
lar disorders related to the placenta are the basic patho-
physiological mechanism in hypertensive pregnancies and
pregnancies with IUGR2,5,8–10.
Despite all knowledge vascular etiology of these dis-
eases are still controversial and unclear. It seems that en-
dothelial cell activation is a center-piece in pathogene-
sis10. Till now, different reports showed that vasospasm
and vascular endothelial injury are two major pathologi-
cal conditions in previous disorders8–10.
Unknown factors provoke activation and dysfunc-
tion of vascular endothelium in placental, maternal and
fetal site.
During normal pregnancy, there is decreases in pe-
ripheral vascular resistance and arterial blood pressure,
increases in cardiac output and vascular compliance, so
called endothelium – dependent vasodilatation10. In PE
there is significant hemodynamic changes; widespread
vasoconstriction, increased vascular resistance and de-
crease cardiac output and vascular compliance. Till now
there’s no relevant studies that support the role of angio-
genic factors in placenta and maternal endothelium in
other PIH such as gestational hypertension and superim-
posed hypertension.
Some studies have suggested that obesity is associ-
ated with hypertensive pregnancy disorders11–13. Increa-
sing body mass index (BMI) was significantly associated
with severity of PIH11. Cardiac output may be higher in
PE patient before the onset of clinical signs of disease,
which is found in pregnant women with higher BMI (14).
Further, some studies claimed that SGA rates are re-
duced in obese mothers, but not as causative factor14–16.
Otherwise some multiple regression analysis suggesting
a causal link between high BMI and IUGR13,15. Increa-
sing BMI was significantly associated with severity of
PIH11,14. In systematic review of 13 cohort study search-
ers found that risk of PE doubled increase in pregnancy
BMI17. Clinical signs of these are suddenly weight gain
demonstrated by visible or invisible edema. It could be
speculated that »volume stroke« in these women could be
additional cause of damaged endothelial cells which in
turn secrete substances in maternal and fetal circulation
that promote and increase sensitivity to vasopressors:
prostaglandins, nitric oxide, angiogenic factors and endo-
thelins, especially endothelin-1 (ET1). The main source
of endothelin is vascular endothelial cells. ET-1 is known
as the most potent endogenous vasoconstrictor and is
well known for its role and effect on endothelial cell dys-
function. Endothelial dysfunction includes vasoconstric-
tion, inflammation, thrombosis and microvascular ob-
struction. Mechanism of action of endothelin is fully
understood by ET-1, which binds to two receptors: ET-A
on the smooth muscles of blood vessels with the effect of
vasoconstriction and ET-B, located on the plasma mem-
brane of epithelial cells where it stimulates production of
nitric oxide and prostaglandins from endothelial cells re-
sulting in vasodilatation18.
The main physical stimulus for ET1 synthesis is hy-
poxia19. It is known as specifically marker in only in hy-
pertensive disorders of pregnancy, particularly PE20–22.
ET-1 causes potent vasoconstriction and prolonged el-
evation of blood pressure in experimental models. But re-
lationship between plasma levels of ET-1 and grade of hy-
pertension is inconsistent in humans21. Elevated ET-1
has been detected in the amniotic fluid and blood of preg-
nant women with premature rupture of membranes, in
the newborns with neonatal asphyxia and in the preg-
nancy with IUGR23–27. The main consequence of endo-
thelial dysfunction is the nutritional deficit and meta-
bolic imbalance that occurs when significant percentage
of placental endothelial cells is affected during the preg-
nancy. In that way ET1 could be partly responsible for
intrauterine fetal growth restriction. Placental ischemia
stimulates endothelin production from blood vessels on
both sides of placenta (maternal/fetal) consequently lea-
ding to placental vessel vasoconstriction and hyperten-
sive/hypoxic placental and maternal environment. This
cascade of events reflects on fetal and finally neonatal
state.
Preclinical studies conducted in experimental animal
models demonstrated the importance of ET1 as the main
mediator in the pathophysiology of intrauterine growth
retardation due to ischemic reperfusion injury. The lim-
ited of these studies is distinction of animal and specific
nature of human pregnancies.
The trend is increasing scientific knowledge about the
influence of vasoactive endothelial factors in obstetric
and neonatal studies of physiological processes and pa-
thogenetic disorders in pregnancy and neonatal period.
Most of the previous reports reflect association of in vitro
experiments, animal studies and observation in born in-
fants from hypertensive disorders or/and IUGR rather
than an undoubtful causal relationship. Also there are
conflicting results of influence of maternal anthropome-
tric or other clinic characteristic on previous disorders.
The aim of this study was to explore the influence of
anthropometric and clinical parameters on ET-1 levels in
pregnant women and neonates. This is important since
A. Vukeli} [aruni} et al.: Endothelin-1 Levels in Pregnant Women and Newborns, Coll. Antropol. 36 (2012) 2: 395–400
396
ET-1 levels are concerned as potential maternal or neo-
natal screening marker in pathological pregnancies re-
lated to increased blood pressure.
Subjects and Methods
Ethic approval
This study was approved by the ethic committee of
School of Medicine of Rijeka and Rijeka University Hos-
pital Center. All participants were given a complete de-
scription of the study, and provided written informed
consent.
Subjects
A cross-sectional study was performed on pathological
pregnancies and newborn children of women with: PIH,
IUGR and PIH with IUGR. The examined women deliv-
ered newborns at the Department of Gynecology and ob-
stetrics of the Rijeka University Hospital Center (Croa-
tia) in a 3 years period (January 2009 – December 2011).
The pre-existing hypertension, gestational diabetes and
other pregnancies such as twin pregnancy or infants
with congenital malformations were excluded. Maternal,
obstetric and neonatal records were reviewed. The con-
trol group consisted of 88 healthy pregnant women and
their newborns.
PIH was diagnosed by increased blood pressure dur-
ing pregnancy (>140mmHg systolic and 90 mmHg dia-
stolic), >20 weeks of gestation, with or without proteinu-
ria (=300 mg protein/24 hours?. Pathological pregnancies
were classified as: 1-PIH, 2-IUGR and 3-PIH with IUGR.
The infant birth weight below the 10th percentile for
gestational age was classified as IUGR. Gestational age
was determined from date of last menstrual period or
early dating ultrasound. If the discrepancy was greater
than 7 days, early dating scan was chosen. Gestational
age was confirmed by the neonatologist’s experience on
basis of the New Ballard score. Gestational age was classi-
fied as: 1 – (<30 week), 2 – (31–36 week), 3 – (= 37 week).
We tested the blood for ET-1 levels from mothers dur-
ing third trimester of pregnancy and 4th day after deliv-
ery, when was also taken venous blood of doubly clamped
umbilical cord, which reflected the fetal status.
Therapy was classified as: 1 – women under anti-hy-
pertension therapy and 2 – women with no therapy. De-
livery termination was classified as: 1 – vaginal, 2 – vac-
uum extraction and 3 – caesarean section. Parity was
classified as: 1 – primiparous and 2 – multiparous. Urine
proteins were classified as: 1 – present, 2 – absent. Apgar
score made by neonatologist to examine the newborns
breathing effort, heart rate, muscle tone, reflexes and skin
color. 5 minute Apgar score was classified from 1 to 10.
Methods
ELISA – 8 milliliters of blood were taken and centri-
fuged at 500xg. Serums were frozen at –20°C until the
analysis. Serum endothelin-1 levels were determined by
use of a sandwich Elisa assay according to the manufac-
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TABLE 1
CHARACTERISTICS OF STUDY SUBJECTS
Characteristics Normal pregnancy (N=88) Pathological pregnancy (N=100) p value
Women
Age (years) 30.5±3.6 30±4.2 0.39
Body weight (kg) 83.6±7.9 89.1±17.5 <0.05
Body height (cm) 164.8±5.4 166.9±6.2 <0.05
Body mass index (kg/m2) 30.8±2.9 31.9±5.7 0.08
Systolic pressure 2nd 115±6.1 151±18.4 <0.001
Diastolic pressure 2nd 74.3±4.6 98.3±13.5 <0.001
Systolic pressure 3rd 118.3±7.1 143.5±16.6 <0.001
Diastolic pressure 3rd 78.6±5.7 93.6±11.2 <0.001
Weight gain (kg) 12.5±5 12.8±6.2 0.73
3rd Endothelin-1 (fg/mL) 0.64±0.4 3.92±2 <0.001
P Endothelin-1(fg/mL) 0.58±0.4 3.75±1.9 <0.001
Neonates
Body weight (kg) 3.58±0.4 2.58±1.2 <0.001
Length (cm) 52.3±1.8 46.3±6.6 <0.001
Head circumference (cm) 35.4±1 32.2±4.2 <0.001
UC Endothelin-1 (fg/mL) 0.82±0.4 4.53±2.1 <0.001
2nd – second trimenon, 3rd – third trimenon, UC – umbilical cord, P – (postpartum, 4th day after birth)
turer’s instructions (Biomedica Gruppe, Wien, Austria).
Endothelin-1 levels were measured in range from 0 to10
fmol/mL.
Statistical analysis
After normal distribution of results, parametric tests
were used in statistical analysis. Descriptive analysis as
well as differences between independent groups was per-
formed by use of the Student t-test. Multiple regression
analysis was employed to determine the influence of ma-
ternal parameters on ET-1 levels (Model 1) as well as in-
fluence of neonatal parameters on ET-1 levels (Model 2).
Statistica 8.0 (Stat Soft Inc, Tulsa, United States) was em-
ployed and results were considered significant at p<0.05.
Results
Age, anthropometric and clinical parameters are pre-
sented at the Table 1.
Both regression models significantly predicted ET-1
levels in pathological pregnancies or controls. Only sta-
tistically significant influences of single predictors on
ET-1 levels are presented at Tables 2-4.
Discussion
Results revealed that endothelin-1 serum levels are
significantly predicted by maternal and neonatal param-
eters (Tables 2-4).
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TABLE 2
MULTIPLE REGRESSION ANALYSIS OF 3RD TRIMENON ET-1 ON
»MATERNAL« AND »NEONATAL« PARAMETERS
Model R R2 F p
1 (a) 0.80 0.63 9.66 0.000
2 (c) 0.40 0.15 3.74 0.007
(d) 0.44 0.19 4.51 0.001
a Pathological pregnancies predictors: diagnosis, therapy, parity,
age, body height, body weight, body mass index, systolic blood
pressure 2nd trimenon, diastolic blood pressure 2nd trimenon, sy-
stolic blood pressure 3rd trimenon, diastolic blood pressure 3rd
trimenon, weight gain, urine proteins, gestation age, delivery ter-
mination
c,d Pathological and healthy neonatal predictors: body weight,
body length, head circumference, Apgar score
Model b r p
1 (a) Diagnosis
Therapy


















2 (c) Apgar score –0.53 –0.42 0.000









MULTIPLE REGRESSION ANALYSIS OF 4TH POSTPARTAL DAY
ET-1 ON »MATERNAL« AND »NEONATAL« PARAMETERS











2 (c) 0.45 0.20 4.84 0.001
(d) 0.33 0.11 2.47 0.051
a,b Pathological and healthy pregnancies predictors: diagnosis,
therapy, parity, age, body height, body weight, body mass index,
systolic blood pressure 2nd trimenon, diastolic blood pressure 2nd
trimenon, systolic blood pressure 3rd trimenon, diastolic blood
pressure 3rd trimenon, weight gain, urine proteins, gestation age,
delivery termination
c,d Pathological and healthy neonatal predictors: body weight,
body length, head circumference, Apgar score
Model b r p
1 (a) Diagnosis
Therapy


















(b) Body mass index (kg/m2) 0.19 0.24 0.031
2 (c) Apgar score –0.54 –0.43 0.000









MULTIPLE REGRESSION ANALYSIS OF UMBILICAL CORD ET-1
ON »MATERNAL« AND »NEONATAL« PARAMETERS











2 (c) 0.42 0.17 3.91 0.003
(d) 0.32 0.10 2.36 0.050
a,b Pathological and healthy pregnancies predictors: diagnosis,
therapy, parity, age, body height, body weight, body mass index,
systolic blood pressure 2nd trimenon, diastolic blood pressure 2nd
trimenon, systolic blood pressure 3rd trimenon, diastolic blood
pressure 3rd trimenon, weight gain, urine proteins, gestation age,
delivery termination
c,d Pathological and healthy neonatal predictors: body weight,
body length, head circumference, Apgar score
Model b r p
















(b) Body mass index (kg/m2) 0.18 0.23 0.046
2 (c) Apgar score –0.54 –0.39 0.000








ET-1 levels and maternal predictors
In maternal blood ET-1 levels were strongly predicted
by diagnosis, therapy and BMI, while umbilical cord ET-1
levels were strongly predicted by gestational age, therapy
and delivery termination.
Our results showed proportional relationship be-
tween pregnancy induced diseases (PIH, IUGR) and ma-
ternal ET-1. The highest levels of the maternal ET-1
were found in subgroup PIH with IUGR, which corre-
sponds to majority of similar studies22,26. Anti-hyperten-
sive therapy negatively predicted maternal ET-1 (Tables
2 and 3), which indicates good compliance and possibility
for vascular endothelial cell recovery. Opposite to mater-
nal is positive correlation between umbilical ET-1 and
therapy (Table 4), which argues for week neonatal com-
pliance and strong vasoconstriction due to chronic hy-
poxia27. According to the theory of the vascular damage,
clinical manifestations of hypertension are usually seen
in third pregnancy trimester, but molecular mechanisms
seem to start earlier. Positive correlation between umbil-
ical ET-1 and gestational age is probably compensatory,
due to neonatal response in state of chronic hypoxia23–27.
Contrary to findings of Laforgia et al. who found higher
ET-1 levels in neonates delivered by caesarean section,
our results however, speak for lower ET-1 levels, which
could be referred to a large number of elective caesarean
section.
Recent literature data relates pregnancies with BMI
higher than 30 to hypertensive disorders such as PIH,
particularly preeclampsia11–13. Our findings of the posi-
tive correlation between BMI and ET-1 levels in patho-
logical pregnancies are expected and evidence based, but
the same finding in controls suggest that obese pregnant
women have increased risk for cardiovascular diseases.
ET-1 levels and neonatal predictors
In pathological pregnancies, ET-1 levels were strongly
predicted by Apgar score. Expected, Apgar score inver-
sely correlated to maternal and neonatal ET-1 levels,
which is similar to Laforgia et al.24. Except for inverse
correlation between ET-1 levels and Apgar score in con-
trols, direct correlation between ET-1 and neonatal wei-
ght is found to be expected, since healthy newborns did
not suffer from compromised circulation due to hypoxia
(Tables 2-4).
Conclusion
Numerous studies have been conducted in past de-
cade as to better understand mechanisms underlying
vascular pathology in hypertensive pregnancies. The role
of vasoconstrictive endothelins is undoubtful, but except
for increased blood pressure, little is known about other
influences of endothelin-1. In this study different clinical
and anthropometric factors were engaged and amongst
others, BMI appeared as important predictor of ET-1 se-
rum levels.
Neonatal 5 minute Apgar score is often based on sub-
jective neonatologist estimation. Therefore, inverse rela-
tionship between Apgar and umbilical ET-1, indicates
that ET-1 could be understood as a good prognostic
marker in cases of neonatal asphyxia.
R E F E R E N C E S
1. KHAN KS, WOJDYLA D, SAY L, GULMEZOGLU AM, VAN LOOK
PF, Lancet, 367 (2006) 1066. DOI: 10.1016/S0140-6736(06)68397-9. — 2.
ROBERTS JM, PEARSON G, CUTLER J, LINDHEIMER M, Hyperten-
sion, 41 (2003) 437. — 3. ROBERTS JM, VONVERSEN-HOEYNCK F,
Hypertension, 49 (2007) 15. — 4. XIONG X, DEMIANCZUK NN, SAUN-
DERS LD, WANG FL, FRASER WD, Am J Epidemiol, 155 (2002) 203. —
5. REDMAN CW, SARGENT IL, Science, 308 (2005) 1592. DOI: 10.1126/
science.1111726. — 6. ROMO A, CARCELLER R, TOBAJAS J, Pediatr
Endocrinol Rev, 6 (2009) 332. — 7. MAULIK D, Clinical Obstetrics and
Gynecology, 49 (2006) 214. DOI: 10.1097/00003081-200606000-00004. —
8. ROBERTS JM,GAMMHILL HS, Hypertension, 46 (2005) 1243. DOI:
10.1161/01.HYP.0000188703.27002.14. — 9. CHAMBERS JC, FUSI L,
MALIK IS, HASKARD DO, DE SWIET M, KOONER JS, JAMA, 285
(2001) 1607. — 10. KHAN F, BELCH JJ, MACLEOD M, MIRES G, Hy-
pertension, 46 (2005) 1123. — 11. SAEED F, JAWAD A, AZMAT A, AZAM
I, KAGAZWALA S, J Pak Med Assoc, 61 (2011) 58. — 12. SEBIRE NJ,
JOLLY M, HARRIS JP, WADSWORTH J, JOFFE M, BEARD RW, REGAN
L, ROBINSON S, International Journal of Obesity, 25 (2001) 1175. DOI:
10.1038/sj.ijo.0801670. — 13. CARR DB, EPPLEIN M, JOHNSON CO,
EASTERLING TR, CRITCHLOW CW, Am J Obstet Gynecol, 193 (2005)
965. DOI: 10.1016/j.ajog.2005.06.034. — 14. CNATTINGIUS S, BERG-
STROM R, LKIPWORTH L, KRAMER MS, New Engl J Med, 338 (1998)
147. DOI: 10.1056/NEJM199801153380302. — 15. GARDOSI J, Best
Practice & Research Clinical Obstetrics and Gynaecology, 23 (2009) 741.
DOI: 10.1016/j.bpobgyn.2009.09.001. — 16. [EGREGUR J, Gynaecol
Perinatol, 17 (2008) 9. — 17. O’BRIEN TE, RAY JG, CHAN WS, Epidemi-
ology, 14 (2003) 368. DOI: 10.1097/00001648-200305000-00020. — 18.
RUBANY GM, POLOKOF MA, J Pharmacol Rev, 45 (1994) 325. — 19.
JAIN SK, YADAVA R, RAIKAR R, JIACM, 3 (1) (2002) 59. — 20. NEZAR
MA, EL-BAKY AM, SOLIMAN OA, ABDEL-HADY HA, HAMMAD AM,
AL-HAGGAR MS, Journal of Indian Paediatric, 76 (2009) 485. DOI:
10.1007/s12098-009-0079-0. — 21. LYGNOS MC, PAPPA KI, PAPADAKI
HA, RELAKIS C, KOUMANTAKIS E, ANAGNOU NP, ELIOPOULOS GD,
In Vivo, 20 (1) (2006) 157. — 22. SAITO Y,NAKAO K, MUKOYAMA M,
IMURA H, N Engl J Med, 322 (1990) 205. — 23. TEKIN N, DINLEYICI
EC, AKSIT MA, KURAL N, EROL K, Neuro Endocrinol Lett, 28 (2007)
284. — 24. LAFORGIA N, DIFONZO I, ALTOMARE M, MAUTONE A,
Acta Paediatrica, 90 (2001) 351. DOI: 10.1111/j.1651-2227.2001. tb00317.
x. — 25. SHARMA D, SINGH A, TRIVEDI SS, BHATTACHARJEE J, Am
J Reprod Immunol, 65 (2011) 428. DOI: 10.1111/j.1600-0897.2010.00903.
x. — 26 ERDEM A, ERDEM M, HIMMETOGLU O, YILDIRIM G, ARS-
LAN M, Journal of Perinatal Medicine, 31 (2003) 52. DOI: 10.1515/JPM.
2003.008. — 27. ISOZAKI-FUKUDA Y, KOJIMA T, HIRATA Y, ONO A,
SAWARAGI S, SAWARAGI I, KOBAYASHI Y, Pediatr Res, 30 (1991) 244.
DOI: 10.1203/00006450-199109000-00008.
A. Vukeli}-[aruni}
University of Rijeka, Rijeka University Hospital Center, Department of Perinatology, Clinic for Gynecology, Kre{imirova 42,
51000 Rijeka Croatia
e-mail: alenka7@net.hr
A. Vukeli} [aruni} et al.: Endothelin-1 Levels in Pregnant Women and Newborns, Coll. Antropol. 36 (2012) 2: 395–400
399
UTJECAJ KLINI^KIH I ANTROPOMETRIJSKIH PARAMETARA NA SERUMSKU KONCENTRACIJU
ENDOTELINA – 1 U TRUDNICA I NJIHOVE NOVORO\EN^ADI
S A @ E T A K
Hipertenzija u trudno}i, glavni je razlog smrti majki u zemljama u razvoju. Endotelin – 1 je najja~i poznati vazokon-
striktorni ~imbenik, a njegova serumska koncentracija je povi{ena u hipertenzivnim trudno}ama. Stoga je va`no utvr-
diti ~imbenike majke i novoro|en~eta, koji utje~u na serumsku koncentraciju ET-1. U 100 hipertenzivnih trudno}a i 88
kontrola, krvi su analizirane za serumski ET-1 te su prikupljeni antropometrijski i klini~ki parametri majki i novo-
ro|en~adi. Utvr|eni su zna~ajni utjecaji dijagnoze, terapije i indeksa tjelesne mase (ITM) na maj~ine vrijednosti ET-1.
Tako|er je utvr|en zna~ajan utjecaj gestacijske dobi, terapije i na~ina dovr{enja poroda na umbilikalne vrijednosti
ET-1. Upravo razmjeran odnos izme|u indeksa tjelesne mase i koncentracije ET-1 sugerira da trudnice s velikim ITM
imaju pove}an rizik za kardiovaskularne bolesti. Obrnuto razmjeran odnos Abgara i ET-1 upu}uje da bi ET-1 mogao biti
va`an prognosti~ki marker u slu~aju neonatalne asfiksije.
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